GBI Research forecasts $2.3B solid tumor market
NEW YORK—GBI Research notes in its latest report, “Solid Tumors Market in Asia Pacific to 2019: New Drug Approvals and Anticipated Product Launches to Trigger a Shift in Treatment Paradigm to Targeted Therapies,” that the Asia-Pacific solid tumor treatment markets—specifically ovarian, prostate, bladder and pancreatic cancers—are expected to grow at a CAGR of 12.3 percent, reaching $2.3 billion in 2019. The market reached $1 billion in 2012. The report names Australia as the fastest-growing market for solid tumors in the region, with a CAGR of 13.9 percent. India is expected to see a CAGR of 9.7 percent, with China’s market growing at a rate of 5.5 percent. Average treatment costs for these cancers are expected to increase as well, growing by 6.5 percent from $4,001 in 2012 to $6,212 by 2019.